Enlarged facial pore Good health enlarged pores facial pore calcium hydroxylapatite cross-linked hyaluronic acid
Conditions
Interventions
The premixed solution, CaHA 1.5ml, HA 1.0ml, and NSS 6.0ml, is injected using blunt 22G cannula into subcutaneous layer in the cheek area. ,The CaHA solution, CaHA1.5ml, and NSS6.0ml, is injected usin
Experimental Drug,Active Comparator Drug
premixed CaHA and HA,comparator
Sponsors
Division of Dermatology, Department of medicine, Faculty of Medicine, Ramathibodi hospital
Merz healthcare (Thailand) company limited
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The participant must be older than 18 years old. 2. Having even enlarged facial pores for both sides 3. No severe co-morbidity
Exclusion criteria
Exclusion criteria: 1. Having the active facial skin infection 2. Have been treated enlarged facial pore with botulinum toxin within 6 months 3. Have been treated with ablative laser, radiofrequency, or chemical peel within 3 months 4. Have been injected with biostimulators, HA, PLLA, PDLLA, PCL, or CaHA, for enlarged facial pores within 2 years 5. Have been treated with thread implant within 2 years 6. Having a history of keloid 7. Having abnormal coagulation 8. Having a history of allergic to HA filler, or CaHA products 9. Pregnancy or breast feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mean pore size 0, 4, 8, 12, 16, 20, 24, and 28 weeks Using Antera3D imaging system capture the cheek area | — |
Secondary
| Measure | Time frame |
|---|---|
| Global aesthetic improvement scale 4, 8, 12, 16, 20, 24, and 28 weeks Using Trica3D photobooth capture the whole face. Evaluate the global aesthetic improvement scale by compare with the baseline picture.,Pain score after the treatment The participant is instructed to evaluate the pain score by using visual analog scale, marking the pain on the 10 cm in horizon line after the treatment.,texture score 0, 4, 8, 12, 16, 20, 24, and 28 weeks Using Antera3D imaging system capture the cheek area,Jawline assessment 0, 4, 8, 12, 16, 20, 24, and 28 weeks Using Nikon5100D digital camera capture the 45 degree angle of both sides to evaluate the jawline. And using Merz asthetic scale for Jawline to assess the jawline assessment,Adverse events 4, 8, 12, 16, 20, 24, and 28 weeks Evaluate the facial swelling, pain, and bruise duration by asking the participant. The assessor physician inspects and palpates the cheek area of treatment to identify the nodule, lumping, bruise. ,Adverse events 4, 8, 12, 16, 20, 24, and 28 weeks Asking the participant about the facial expression change after injection,Adverse events 4, 8, 12, 16, 20, 24 ,and 28 weeks The physician inspects cautiously sign of inflammations, redness, pain, or warm. | — |
Countries
Thailand
Contacts
Public ContactVasanop Vachiramon
Faculty of Medicine Ramathibodi hospital, Mahidol university
Outcome results
None listed